Company Overview

Vaxxinity, Inc. is a U.S.-based, clinical stage biotechnology company, that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. Vaxxinity has a proprietary technology platform that has enabled the innovation of synthetic peptide vaccines designed to treat and prevent chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia, as well as infectious diseases, including COVID-19. Vaxxinity has designed its pipeline to achieve a historic global impact on human health.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

11 Nov '21
DALLAS, Texas , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the pricing of its initial public offering of 6,000,000 shares of class A common stock at a public offering price
01 Apr '21
New U.S. corporation consolidates chronic and infectious disease vaccines and immunotherapeutics to democratize health on a global scale DALLAS, TX  (April 1, 2021)  – COVAXX and United Neuroscience today announced the consolidation of their vaccine development efforts under the newly formed

Events

More events are coming soon.

Featured Reports

More information is coming soon.